Jenburkt Pharmaceuticals Ltd

Jenburkt Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Jenburkt Pharmaceuticals Ltd

₹ 1,177 0.93%
13 May - close price
jenburkt.com BSE: 524731
About

Incorporated in 1985, Jenburkt Pharmaceuticals Ltd manufactures and markets branded Pharmaceuticals and health care products[1]

Key Points

Business Overview:[1]
JPL manufactures and markets pharmaceutical formulations in India and internationally across 13 countries. It promotes 85 brands across 1 Lac+ doctors regularly. Company has 1,000+ stockists and its reach extends to 4 Lac+ pharmacies across the globe. JPL caters to large government, semi-government institutions, missionary hospitals, public sector enterprises, etc.

Website BSE
  • Market Cap ₹ 519 Cr.
  • Current Price ₹ 1,177
  • High / Low ₹ 1,410 / 944
  • Stock P/E 13.8
  • Book Value ₹ 446
  • Dividend Yield 1.53 %
  • ROCE 27.2 %
  • ROE 20.4 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 25.7%

Cons

  • The company has delivered a poor sales growth of 9.08% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
35 29 38 36 39 33 41 37 41 36 46 43 45
28 22 29 28 29 23 30 28 30 27 32 36 30
Operating Profit 7 7 9 7 10 9 11 9 11 9 13 7 14
OPM % 21% 24% 24% 20% 25% 29% 28% 24% 26% 25% 29% 17% 32%
1 1 1 1 1 1 2 2 2 2 2 2 0
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 1 0 1 1 1 1 1 1 1 1 1 1 1
Profit before tax 8 7 10 8 10 10 13 10 12 10 14 8 14
Tax % 21% 28% 23% 31% 24% 26% 23% 32% 28% 23% 29% 29% 21%
6 5 7 5 8 7 10 7 9 8 10 6 11
EPS in Rs 14.39 12.17 16.59 12.24 17.86 16.81 21.75 14.75 19.35 17.65 23.02 13.44 24.58
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
85 94 103 115 123 119 109 124 137 142 152 169
70 77 84 91 98 99 89 97 106 109 111 125
Operating Profit 15 16 20 24 25 20 20 27 30 33 40 44
OPM % 18% 18% 19% 21% 20% 17% 18% 22% 22% 23% 27% 26%
2 3 3 3 3 4 4 5 5 5 7 6
Interest 0 0 0 0 0 1 0 0 0 0 0 0
Depreciation 3 2 2 2 1 2 2 2 2 2 3 3
Profit before tax 14 17 20 25 27 21 22 30 33 35 44 47
Tax % 33% 36% 34% 32% 26% 30% 24% 25% 25% 26% 27% 25%
10 11 14 17 20 15 16 22 25 26 32 35
EPS in Rs 20.76 23.19 29.06 37.50 43.14 32.40 35.95 48.59 55.76 58.87 72.64 78.72
Dividend Payout % 30% 31% 28% 24% 24% 25% 28% 25% 26% 26% 25% 26%
Compounded Sales Growth
10 Years: 6%
5 Years: 9%
3 Years: 7%
TTM: 11%
Compounded Profit Growth
10 Years: 13%
5 Years: 18%
3 Years: 15%
TTM: 20%
Stock Price CAGR
10 Years: 10%
5 Years: 20%
3 Years: 17%
1 Year: 14%
Return on Equity
10 Years: 21%
5 Years: 20%
3 Years: 20%
Last Year: 20%

Balance Sheet

Figures in Rs. Crores

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 5 5 5 5 5 5 5 5 4 4 4 4
Reserves 29 36 50 57 73 75 94 113 118 141 167 193
7 5 6 0 7 3 5 7 3 0 4 2
21 12 16 16 18 21 17 18 16 19 19 26
Total Liabilities 61 58 76 77 103 104 120 143 141 164 195 226
12 12 11 10 10 12 11 11 10 10 15 19
CWIP 0 0 0 0 1 0 0 0 1 1 40 46
Investments 0 1 2 5 5 4 7 8 11 17 21 27
49 45 64 62 87 88 103 123 119 136 120 133
Total Assets 61 58 76 77 103 104 120 143 141 164 195 226

Cash Flows

Figures in Rs. Crores

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
9 8 10 16 13 15 19 9 17 8 28 27
1 -0 -10 1 -11 -3 -19 -1 3 -1 -17 -19
1 -5 1 -18 -2 -11 -1 -6 -21 -7 -8 -9
Net Cash Flow 11 2 1 -1 0 1 -0 3 -1 0 3 -2
Free Cash Flow 8 5 10 16 11 11 18 7 15 6 8 13
CFO/OP 88% 82% 85% 103% 80% 104% 127% 62% 83% 49% 102% 88%

Ratios

Figures in Rs. Crores

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 32 23 32 40 68 55 47 45 45 50 50 53
Inventory Days 107 109 128 73 99 120 92 115 92 103 109 154
Days Payable 54 44 72 44 66 58 56 83 67 75 100 91
Cash Conversion Cycle 85 88 89 69 101 117 83 77 70 78 59 115
Working Capital Days -11 6 10 25 35 32 17 16 31 36 31 41
ROCE % 42% 40% 39% 42% 37% 26% 24% 26% 27% 26% 27% 27%

Insights

In beta
Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Number of Permanent Employees
Number

Log in to view insights

Please log in to see hidden values.

Login
R&D Expenditure - Total
₹ Lacs
Trade Receivables Turnover
Times
Medical Representatives / Field Force
Number

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
47.56% 47.42% 47.39% 47.23% 46.71% 46.71% 46.69% 46.68% 46.67% 46.66% 46.65% 46.64%
1.79% 1.38% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.12% 0.12% 0.12% 0.12% 0.12% 0.12%
50.65% 51.21% 52.63% 52.78% 53.29% 53.28% 53.20% 53.20% 53.21% 53.22% 53.24% 53.24%
No. of Shareholders 5,7415,8726,0216,3166,4196,6286,9016,9876,7126,8557,1636,999

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings